TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion.
Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker
Click arrow to play
Download TWiV 879 (75 MB .mp3, 124 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- ASV 2022 3:11
- Emergence of remdesivir resistance (Nature Comm) 9:30
- How to stall a copy machine (TWiV 819) 10:44
- Omicron altered TMPRSS2 usage (Nature) 35:18
- Timestamps by Jolene. Thanks!
Weekly Picks 1:21:44
Brianne – NSURP 2022
Kathy – Virology Jobs
Rich – 10 Steps from Seed to Cup (Graphic)
Alan – Fathoms: The World in The Whale, by Rebecca Giggs
Vincent – Worldwaterday.org
Listener Picks
Jeremy – Archaeology of Light
Intro music is by Ronald Jenkees
Send your virology questions and comments to twiv@microbe.tv
Since studies have now demonstrated that unlike Delta and other previous versions of the SARS-C0V-2 the Omicron variant prefers endosomal entry, it follows that chloroquine/hydroxychloroquine might be a clinically useful therapy! In vitro data revealed that chloroquine inhibited SARS-CoV-1, which also prefers the endosomal route, led to the idea that chloroquine would also work for SARS=-CoV-2 which it did not because up until Omicron all the versions have preferred direct entry using TMPRES2.